[1] BEZERRA D P, PESSOA C, DE MORAES M O, et al.Overview of the therapeutic potential of piplartine (piperlongumine)[J]. Eur J Pharm Sci, 2013, 48(3):453-463.
[2] NIU M, XU X, SHEN Y, et al. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity[J]. Chem Biol Interact, 2015, 237:66-72.
[3] WIEMANN J, KARASCH J, LOESCHE A, et al. Piperlongumine B and analogs are promising and selective inhibitors for acetylcholinesterase[J]. Eur J Med Chem, 2017, 139:222-231.
[4] ZOU P, XIA Y, JI J, et al. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer[J]. Cancer Lett, 2016, 375(1):114-126.
[5] WANG Y, CHANG J, LIU X, et al. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents[J]. Aging, 2016, 8(11):2915-2926.
[6] SON D J, KIM S Y, HAN S S, et al. Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling[J]. Biochem Biophys Res Commun, 2012, 427(2):349-354.
[7] SEOK J S, JEONG C H, PETRIELLO M C, et al. Piperlongumine decreases cell proliferation and the expression of cell cycle-associated proteins by inhibiting Akt pathway in human lung cancer cells[J]. Food Chem Toxicol, 2018, 111:9-18.
[8] PISKA K, GUNIA-KRZYZAK A, KOCZURKIEWICZ P, et al. Piperlongumine (piplartine) as a lead compound for anticancer agents-synthesis and properties of analogues: a mini review[J]. Eur J Med Chem, 2018, 156:13-20.
[9] XU X, FANG X, WANG J, et al. Identification of novel ROS inducer by merging the fragments of piperlongumine and dicoumarol[J]. Bioorg Med Chem Letters, 2017, 27(5):1325-1328.
[10] MEEGAN M J, NATHWANI S, TWAMLEY B, et al. Piperlongumine (piplartine) and analogues:antiproliferative microtubule-destabilising agents[J]. Eur J Med Chem, 2017, 125:453-463.
[11] ZOU Y, YAN C, ZHANG H, et al. Synthesis and evaluation of, N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents[J]. Eur J Med Chem, 2017, 138:313-319.
[12] KIM Y H, YOON Y J, LEE Y J, et al. Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells[J]. Bioorg Med Chem Lett, 2018,28(14):2566-2572.
[13] SEO Y H, KIM J K, JUN J G .Synthesis and biological evaluation of piperlongumine derivatives as potent anti-inflammatory agents[J]. Bioorg Med Chem Lett, 2014, 24(24):5727-5730.
[14] SUN L D, WANG F, DAI F, et al. Development and mechanism investigation of a new piperlongumine derivative as a potent anti-inflammatory agent[J]. Biochem Pharmacol, 2015, 95(3):156-169.
[15] DAI F, YUAN C H, JI Y, et al. Keto-enol-based modification on piperlongumine to generate a potent Cu(II) ionophore that triggers redox imbalance and death of HepG₂ cells[J]. Free Radic Biol Med, 2018,120:124-132.
[16] PUNGANURU S R, MADALA H R, VENUGOPAL S N, et al. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties[J]. Eur J Med Chem, 2015, 107:233-244.
[17] ZHANG Y, MA H, WU Y, et al. Novel non-trimethoxylphenylpiperlongumine derivatives selectively kill cancer cells[J]. Bioorg Med Chem Lett, 2017,27(11):2308-2312.
[18] LAD N P, KULKARNI S, SHARMA R, et al. Piperlongumine derived cyclic sulfonamides (sultams): synthesis and in vitro exploration for therapeutic potential against HeLa cancer cell lines[J]. Eur J Med Chem, 2017, 126:870-878.
[19] LIU X G, WANG Y Y, ZHANG X, et al. Senolytic activity of piperlongumine analogues: synthesis and biological evaluation[J]. Bioorg Med Chem, 2018,26(14):3925-3938.
[20] WANG Y, WANG J, LI J, et al. Design, synthesis and pharmacological evaluation of novel piperlongumine derivatives as potential antiplatelet aggregation candidate[J]. Chem Biol Drug Des, 2016, 87(6):833-840.
[21] PENG S, ZHANG B, MENG X, et al. Synthesis of piperlongumine analogues and discovery of nuclear factor erythroid 2-related factor 2 (Nrf2) activators as potential neuroprotective agents[J]. J Med Chem, 2015, 58(13):5242-5255.
[22] WANG H B,JIN X L,ZHENG J F, et al. Developing piperlongumine-directed glutathione S-transferase inhibitors by an electrophilicity-based strategy [J]. Eur J Med Chem,2017,126:517-525.
[23] WU Y, MIN X, ZHANG C, et al. Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents[J]. Eur J Med Chem, 2014, 82:545-551.
[24] RAO V R, MUTHENNA P, SHANKARAIAH G, et al. Synthesis and biological evaluation of new piplartine analogues as potent aldose reductase inhibitors (ARIs)[J]. Eur J Med Chem, 2012, 57(11):344-361.
[25] SHARMA R K, OTSUKA M, GABA G, et al. Inhibitors of transcription factor nuclear factor-kappa beta (NF-κβ)-DNA binding[J]. Rsc Adv, 2013, 3(5):1282-1296.
[26] MARQUES L M M, SILVA-JUNIOR E A D, GOUVEA D R, et al. In vitro metabolism of the alkaloid piplartine by rat liver microsomes[J]. J Pharm Biomed Anal, 2014, 95:113-120.